<SEC-DOCUMENT>0000876661-18-001081.txt : 20181009
<SEC-HEADER>0000876661-18-001081.hdr.sgml : 20181009
<ACCEPTANCE-DATETIME>20181009143016
ACCESSION NUMBER:		0000876661-18-001081
CONFORMED SUBMISSION TYPE:	25-NSE
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20181009
DATE AS OF CHANGE:		20181009
EFFECTIVENESS DATE:		20181009

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		25-NSE
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		181113357

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NYSE AMERICAN LLC
		CENTRAL INDEX KEY:			0001143313
		IRS NUMBER:				522127241

	FILING VALUES:
		FORM TYPE:		25-NSE

	BUSINESS ADDRESS:	
		STREET 1:		11 Wall Street
		CITY:			New York
		STATE:			NY
		ZIP:			10005
		BUSINESS PHONE:		212-656-5414

	MAIL ADDRESS:	
		STREET 1:		11 Wall Street
		CITY:			New York
		STATE:			NY
		ZIP:			10005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NYSE MKT LLC
		DATE OF NAME CHANGE:	20120514

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NYSE Amex
		DATE OF NAME CHANGE:	20090402

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NYSE Alternext US LLC
		DATE OF NAME CHANGE:	20081009
</SEC-HEADER>
<DOCUMENT>
<TYPE>25-NSE
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0001143313</cik>
        <entityName>NYSE AMERICAN LLC</entityName>
    </exchange>

    <issuer>
        <cik>725363</cik>
        <entityName>CEL SCI CORP</entityName>
        <fileNumber>001-11889</fileNumber>
        <address>
            <street1>8229 Boone Boulevard Suite 802</street1>
            <city>Vienna</city>
            <stateOrCountryCode>VA</stateOrCountryCode>
            <stateOrCountry>VIRGINIA</stateOrCountry>
            <zipCode>22182</zipCode>
        </address>
        <telephoneNumber>703-506-9460</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Series S Warrant</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(a)(3)</ruleProvision>

    <signatureData>
        <signatureName>Victoria Paper</signatureName>
        <signatureTitle>Senior Analyst</signatureTitle>
        <signatureDate>2018-10-09</signatureDate>
    </signatureData>
</notificationOfRemoval>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.25
<SEQUENCE>2
<FILENAME>ruleprovisionnotice.htm
<TEXT>
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES

The NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 22, 2018, pursuant to the provisions of Rule 12d2-2 (a).

[  X  ] 17 CFR 240.12d2-2(a)(3)  That on October 9, 2018 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right  to receive an immediate cash payment.

Pursuant to the terms of the Warrant Agreement, the Warrant to purchase Common Stock of Cel-Sci Corp will expire on October 11, 2018.  Twenty-five (25) Warrants are required to purchase one share of common stock at an exercise price of $31.25 per share.

The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on October 9, 2018.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
